{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:39:15Z","timestamp":1780540755557,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11926-019-0850-9","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T11:12:33Z","timestamp":1567249953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Recent Advances in Pharmacological Treatments of Adult Dermatomyositis"],"prefix":"10.1007","volume":"21","author":[{"given":"Kristen L.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Zeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"issue":"7","key":"850_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(7):344\u20137. \nhttps:\/\/doi.org\/10.1056\/NEJM197502132920706\n\n.","journal-title":"N Engl J Med"},{"issue":"3","key":"850_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0733-8635(02)00021-9","volume":"20","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387\u2013408.","journal-title":"Dermatol Clin"},{"issue":"1","key":"850_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","volume":"146","author":"MJ Bendewald","year":"2010","unstructured":"Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County. Minnesota Arch Dermatol. 2010;146(1):26\u201330. \nhttps:\/\/doi.org\/10.1001\/archdermatol.2009.328\n\n.","journal-title":"Minnesota Arch Dermatol"},{"issue":"5","key":"850_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/acr.22728","volume":"68","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti\u2013melanoma differentiation\u2013associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res. 2016;68(5):689\u201394.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"850_CR5","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1001\/jamadermatol.2018.5215","volume":"155","author":"Joanie Pinard","year":"2019","unstructured":"\u2022\u2022 Pinard J, Femia AN, Roman M, Alsarheed A, Joyce C, Lin J, et al. Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. JAMA Dermatol. 2019. \nhttps:\/\/doi.org\/10.1001\/jamadermatol.2018.5215\n\n This study examined the systemic treatment of clinically amyopathic dermatomyositis and reported low response to antimalarial therapy despite it being a first-line agent in cutaneous DM.","journal-title":"JAMA Dermatology"},{"issue":"5","key":"850_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.clindermatol.2006.07.001","volume":"24","author":"JP Callen","year":"2006","unstructured":"Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006;24(5):363\u201373. \nhttps:\/\/doi.org\/10.1016\/j.clindermatol.2006.07.001\n\n.","journal-title":"Clin Dermatol"},{"issue":"3","key":"850_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12016-017-8652-1","volume":"53","author":"C Mainetti","year":"2017","unstructured":"\u2022\u2022 Mainetti C, Beretta-Piccoli BT, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):337\u201356. \nhttps:\/\/doi.org\/10.1007\/s12016-017-8652-1\n\n Excellent review covering epidemiology, pathogenesis, clinical manifestations, and treatment of cutaneous dermatomyositis.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"850_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1365-2133.2004.06144.x","volume":"151","author":"M Caproni","year":"2004","unstructured":"Caproni M, Torchia D, Cardinali C, Volpi W, Del Bianco E, D\u2019Agata A, et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol. 2004;151(4):784\u201391.","journal-title":"Br J Dermatol"},{"issue":"3","key":"850_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11926-011-0166-x","volume":"13","author":"L Kao","year":"2011","unstructured":"Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep. 2011;13(3):225\u201332. \nhttps:\/\/doi.org\/10.1007\/s11926-011-0166-x\n\n.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"850_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1365-2133.2008.08967","volume":"160","author":"SA Greenberg","year":"2009","unstructured":"Greenberg SA, Fiorentino D. Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle. Br J Dermatol. 2009;160(2):464\u20136. \nhttps:\/\/doi.org\/10.1111\/j.1365-2133.2008.08967\n\n.","journal-title":"Br J Dermatol"},{"issue":"1","key":"850_CR11","doi-asserted-by":"publisher","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","volume":"7","author":"D Wong","year":"2012","unstructured":"Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One. 2012;7(1):e29161. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0029161\n\n.","journal-title":"PLoS One"},{"issue":"5 Pt 1","key":"850_CR12","first-page":"824","volume":"34","author":"LA Drake","year":"1996","unstructured":"Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(5 Pt 1):824\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"850_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.14726","volume":"179","author":"J Callander","year":"2018","unstructured":"\u2022\u2022 Callander J, Robson Y, Ingram J, Piguet V. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. Br J Dermatol. 2018;179(6):1248\u201355. \nhttps:\/\/doi.org\/10.1111\/bjd.14726\n\n A systematic review of treatment of clinically amyopathic dermatomyositis reporting a majority of patients require more than one treatment due to refractoriness or side effects.","journal-title":"Br J Dermatol"},{"issue":"3","key":"850_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/ddg.12909","volume":"14","author":"C Sunderk\u00f6tter","year":"2016","unstructured":"\u2022\u2022 Sunderk\u00f6tter C, Nast A, Worm M, Dengler R, D\u00f6rner T, Ganter H, et al. Guidelines on dermatomyositis\u2013excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges. 2016;14(3):321\u201338. \nhttps:\/\/doi.org\/10.1111\/ddg.12909\n\n This report details guidelines of treatment for dermatomyositis in Germany as it pertains to skin or muscle disease.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"850_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1346-8138.14604","volume":"29","author":"H Kohsaka","year":"2019","unstructured":"\u2022\u2022 Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol. 2019;29(1):1\u20139. \nhttps:\/\/doi.org\/10.1111\/1346-8138.14604\n\n This report details treatment guidelines of dermatomyositis in Japan as it pertains to skin, lung, and muscle disease.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"850_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","volume":"3","author":"CO Anyanwu","year":"2017","unstructured":"Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP. The systemic management of cutaneous dermatomyositis: results of a stepwise strategy. Int J Womens Dermatol. 2017;3(4):189\u201394. \nhttps:\/\/doi.org\/10.1016\/j.ijwd.2017.05.001\n\n.","journal-title":"Int J Womens Dermatol"},{"issue":"8","key":"850_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/ced.13607","volume":"43","author":"F Galimberti","year":"2018","unstructured":"\u2022 Galimberti F, Kooistra L, Li Y, Chatterjee S, Fernandez AP. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clin Experimental Dermatol. 2018;43(8):906\u201312. \nhttps:\/\/doi.org\/10.1111\/ced.13607\n\n This retrospective study found IVIg to be an effective treatment for refractory cutaneous dermatomyositis, allowing for a decrease or discontinuation of immunosuppressive medication in 80% of patients.","journal-title":"Clin Experimental Dermatol"},{"issue":"9","key":"850_CR18","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/jdv.12223","volume":"28","author":"T Bounfour","year":"2014","unstructured":"Bounfour T, Bouaziz JD, Bezier M, Cordoliani F, Saussine A, Petit A, et al. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol. 2014;28(9):1150\u20137. \nhttps:\/\/doi.org\/10.1111\/jdv.12223\n\n.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"850_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4137\/CCRPM.S23313","volume":"9","author":"H Kawasumi","year":"2015","unstructured":"Kawasumi H, Gono T, Kawaguchi Y, Yamanaka H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;9:9\u201317. \nhttps:\/\/doi.org\/10.4137\/CCRPM.S23313\n\n.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"issue":"4","key":"850_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","volume":"78","author":"DJ Kurtzman","year":"2018","unstructured":"Kurtzman DJ, Vleugels RA. Anti-melanoma differentiation\u2013associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4):776\u201385. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2017.12.010\n\n.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"850_CR21","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","volume":"62","author":"PA Morganroth","year":"2010","unstructured":"Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62(10):1496\u2013501. \nhttps:\/\/doi.org\/10.1002\/acr.20212\n\n.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"850_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3899\/jrheum.180778","volume":"46","author":"H Hozumi","year":"2019","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, et al. Efficacy of glucocorticoids and Calcineurin inhibitors for anti-aminoacyl-tRNA Synthetase antibody\u2013positive polymyositis\/dermatomyositis\u2013associated interstitial lung disease: a propensity score\u2013matched analysis. J Rheumatol. 2019;46(5):509\u201317. \nhttps:\/\/doi.org\/10.3899\/jrheum.180778\n\n.","journal-title":"J Rheumatol"},{"issue":"1","key":"850_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","volume":"54","author":"T Kurita","year":"2014","unstructured":"Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatol. 2014;54(1):39\u201344.","journal-title":"Rheumatol."},{"issue":"2","key":"850_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","volume":"18","author":"T Barba","year":"2019","unstructured":"\u2022\u2022 Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev. 2019;18(2):113\u201322. \nhttps:\/\/doi.org\/10.1016\/j.autrev.2018.07.013\n\n This meta-analysis including 553 patients evaluated the efficacy of treatments used in the management of idiopathic inflammatory myositis associated interstitial lung disease.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"850_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","volume":"36","author":"DJ Go","year":"2016","unstructured":"Go DJ, Park JK, Kang EH, Kwon HM, Lee YJ, Song YW, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int. 2016;36(1):125\u201331. \nhttps:\/\/doi.org\/10.1007\/s00296-015-3328-8\n\n.","journal-title":"Rheumatol Int"},{"issue":"5","key":"850_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/09546634.2017.1403549","volume":"29","author":"V Isak","year":"2018","unstructured":"Isak V, Jorizzo JL. Recent developments on treatment strategies and the prognosis of dermatomyositis: a review. J Dermatolog Treat. 2018;29(5):450\u20139. \nhttps:\/\/doi.org\/10.1080\/09546634.2017.1403549\n\n.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"850_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.nmd.2015.04.013","volume":"25","author":"NE Johnson","year":"2015","unstructured":"Johnson NE, Arnold WD, Hebert D, Gwathmey K, Dimachkie MM, Barohn RJ, et al. Disease course and therapeutic approach in dermatomyositis: a four-center retrospective study of 100 patients. Neuromuscul Disord. 2015;25(8):625\u201331. \nhttps:\/\/doi.org\/10.1016\/j.nmd.2015.04.013\n\n.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"850_CR28","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MJT.0b013e3182987983","volume":"22","author":"T Mathur","year":"2015","unstructured":"Mathur T, Manadan AM, Thiagarajan S, Hota B, Block JA. Corticosteroid monotherapy is usually insufficient treatment for idiopathic inflammatory myopathy. Am J Ther. 2015;22(5):350\u20134. \nhttps:\/\/doi.org\/10.1097\/MJT.0b013e3182987983\n\n.","journal-title":"Am J Ther"},{"issue":"10019","key":"850_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"\u2022\u2022 Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671\u20138. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(15)01021-1\n\n Clinical trial in juvenile dermatomyositis reporting improved response with prednisone and ciclosporin or prednisone and methotrexate compared to prednisone alone.","journal-title":"Lancet"},{"issue":"12","key":"850_CR30","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","volume":"34","author":"Y Ge","year":"2015","unstructured":"Ge Y, Zhou H, Shi J, Ye B, Peng Q, Lu X, et al. The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review. Clin Rheumatol. 2015;34(12):2097\u2013103. \nhttps:\/\/doi.org\/10.1007\/s10067-015-3065-0\n\n.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"850_CR31","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/1756-185X.12931","volume":"19","author":"KI Ueno","year":"2016","unstructured":"Ueno KI, Shimojima Y, Kishida D, Sekijima Y, Ikeda SI. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. Int J Rheum Dis. 2016;19(12):1322\u201330. \nhttps:\/\/doi.org\/10.1111\/1756-185X.12931\n\n.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"850_CR32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3109\/14397595.2015.1029239","volume":"25","author":"Y Yokoyama","year":"2015","unstructured":"Yokoyama Y, Furuta S, Ikeda K, Hirose K, Nakajima H. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod Rheumatol. 2015;25(6):888\u201392. \nhttps:\/\/doi.org\/10.3109\/14397595.2015.1029239\n\n.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"850_CR33","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143(6):763\u20137. \nhttps:\/\/doi.org\/10.1001\/archderm.143.6.763\n\n.","journal-title":"Arch Dermatol"},{"issue":"2","key":"850_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","volume":"56","author":"R Aggarwal","year":"2016","unstructured":"Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology. 2016;56(2):247\u201354. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kew396\n\n.","journal-title":"Rheumatology."},{"issue":"1","key":"850_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s42358-018-0030-z","volume":"58","author":"FH de Souza","year":"2018","unstructured":"de Souza FH, Miossi R, de Moraes JC, Bonf\u00e1 E, Shinjo SK. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Advances in Rheumatology. 2018;58(1):31. \nhttps:\/\/doi.org\/10.1186\/s42358-018-0030-z\n\n.","journal-title":"Advances in Rheumatology"},{"issue":"3","key":"850_CR36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum. 2014;66(3):740\u20139.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"850_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","volume":"18","author":"P Saunders","year":"2017","unstructured":"\u2022\u2022 Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275 The first randomized controlled trial to study the efficacy of rituximab as first-line therapy for connective tissue disease-associated interstitial lung disease.","journal-title":"Trials"},{"key":"850_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","volume":"15","author":"M Pombo-Suarez","year":"2019","unstructured":"Pombo-Suarez M, Gomez-Reino JJ. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15:319\u201326.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"850_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","volume":"77","author":"A Tj\u00e4rnlund","year":"2018","unstructured":"\u2022\u2022 Tj\u00e4rnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Stud\u00fdnkov\u00e1 JT, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77(1):55\u201362 A clinical trial evaluating the efficacy of abatacept in adult patients with dermatomyositis or polymyositis.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"850_CR40","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.jid.2017.05.035","volume":"137","author":"ES Robinson","year":"2017","unstructured":"Robinson ES, Alves P, Bashir MM, Zeidi M, Feng R, Werth VP. Cannabinoid reduces inflammatory cytokines, tumor necrosis factor-\u03b1, and type I interferons in dermatomyositis in vitro. J Investig Dermatol. 2017;137(11):2445\u20137.","journal-title":"J Investig Dermatol"},{"key":"850_CR41","unstructured":"Werth VP, Hejazi E, Pena SM, Haber JS, Okawa J, Feng R, Gabre K, Concha J, Cornwall C, Dgetluck N, Constantine S, White B. A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). \nhttps:\/\/acrabstracts.org\/abstract\/a-phase-2-study-of-safety-and-efficacy-of-anabasum-jbt-101-a-cannabinoid-receptor-type-2-agonist-in-refractory-skin-predominant-dermatomyositis\/\n\n. Accessed January 26, 2019."},{"issue":"8","key":"850_CR42","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJ Kurtzman","year":"2016","unstructured":"Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatology. 2016;152(8):944\u20135.","journal-title":"JAMA Dermatology"},{"issue":"5","key":"850_CR43","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.jid.2018.03.510","volume":"128","author":"A Alsarheed","year":"2018","unstructured":"Alsarheed A, Patel M, Vleugels R. 503 Tofacitinib for recalcitrant cutaneous dermatomyositis. J Investig Dermatol. 2018;128(5):S85.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"850_CR44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","volume":"58","author":"S Moghadam-Kia","year":"2019","unstructured":"Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology. 2019;58(6):1011\u20135 3.","journal-title":"Rheumatology."},{"issue":"12","key":"850_CR45","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology. 2018;57(12):2114\u20139.","journal-title":"Rheumatology."},{"key":"850_CR46","unstructured":"Paik JJ, Albayda J, Tiniakou E, Koenig A, Christopher-Stine L. Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). \nhttps:\/\/acrabstracts.org\/abstract\/study-of-tofacitinib-in-refractory-dermatomyositis-stir-an-open-label-pilot-study-in-refractory-dermatomyositis\/\n\n. Accessed February 23, 2019."},{"issue":"26","key":"850_CR47","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"850_CR48","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/art.22358","volume":"55","author":"HA Hall","year":"2006","unstructured":"Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor \u03b1 inhibitor. Arthritis Care Res: Official Journal of the American College of Rheumatology. 2006;55(6):982\u20134.","journal-title":"Arthritis Care Res: Official Journal of the American College of Rheumatology"},{"issue":"7","key":"850_CR49","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","volume":"146","author":"R Klein","year":"2010","unstructured":"Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor\u2013associated dermatomyositis. Arch Dermatol. 2010;146(7):780\u20134.","journal-title":"Arch Dermatol"},{"issue":"1","key":"850_CR50","first-page":"192","volume":"39","author":"G Riolo","year":"2012","unstructured":"Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol. 2012;39(1):192\u20134.","journal-title":"J Rheumatol"},{"issue":"2","key":"850_CR51","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.alit.2017.09.001","volume":"67","author":"M Takata","year":"2018","unstructured":"Takata M, Yamasaki A, Yamada N, Hagino H, Funaki Y, Harada T, et al. A case of clinically amyopathic dermatomyositis that developed during anti-TNF-\u03b1 therapy for rheumatoid arthritis. Allergol Int. 2018;67(2):286\u20138.","journal-title":"Allergol Int"},{"issue":"6","key":"850_CR52","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","volume":"47","author":"A Schiffenbauer","year":"2018","unstructured":"Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018;47(6):858\u201364.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"850_CR53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jdcr.2018.11.019","volume":"5","author":"C Bitar","year":"2019","unstructured":"Bitar C, Maghfour J, Ho-Pham H, Stumpf B, Boh E. Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients. JAAD Case Reports. 2019;5(2):191\u20134.","journal-title":"JAAD Case Reports"},{"issue":"1","key":"850_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73(1):256\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"850_CR55","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/rheumatology\/ket413","volume":"53","author":"X Guo","year":"2013","unstructured":"Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, et al. Suppression of soluble T cell-associated proteins by an anti-interferon-\u03b1 monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology. 2013;53(4):686\u201395.","journal-title":"Rheumatology."},{"issue":"5","key":"850_CR56","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"\u2022\u2022 Huard C, Gull\u00e0 SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis. Br J Dermatol. 2017;176(5):1224\u201330 Translational study linking the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) with the type 1 interferon pathway biomarkers, particularly interferon-\u03b2.","journal-title":"Br J Dermatol"},{"issue":"5","key":"850_CR57","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","volume":"73","author":"M Zong","year":"2014","unstructured":"Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014;73(5):913\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"850_CR58","first-page":"904","volume":"33","author":"M Groh","year":"2015","unstructured":"Groh M, Rogowska K, Monsarrat O, Deno\u00ebl A, Blanche P, Guillevin L. Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy. Clin Exp Rheumatol. 2015;33(6):904\u20135.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"850_CR59","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","volume":"53","author":"M Kondo","year":"2014","unstructured":"Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology. 2014;53(10):1907\u20138.","journal-title":"Rheumatology."},{"issue":"5","key":"850_CR60","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","volume":"77","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77(5):720\u20137.","journal-title":"Ann Rheum Dis"},{"key":"850_CR61","unstructured":"Fernandez A. Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). \nhttps:\/\/acrabstracts.org\/abstract\/interim-results-of-an-open-label-study-assessing-efficacy-and-safety-of-adrenocorticotropic-hormone-gel-for-treatment-of-refractory-cutaneous-manifestations-of-dermatomyositis\/\n\n. Accessed March 18, 2019."}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-019-0850-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:36:39Z","timestamp":1598744199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-019-0850-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1007\/s11926-019-0850-9","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,31]]},"assertion":[{"value":"31 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors are employed by the University of Pennsylvania, which owns the copyright for the CDASI. VPW is the principal investigator of Lenabasum in DM.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"53"}}